Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$813K Buy
+16,000
New +$746K 0.04% 397
2022
Q4
Sell
-10,000
Closed -$1.18M 1047
2022
Q3
$1.18M Sell
10,000
-8,300
-45% -$1.26M 0.06% 308
2022
Q2
$2.61M Sell
18,300
-9,200
-33% -$1.32M 0.11% 235
2022
Q1
$4.74M Sell
27,500
-9,100
-25% -$1.53M 0.17% 109
2021
Q4
$9.3M Buy
36,600
+13,500
+58% +$3.95M 0.33% 58
2021
Q3
$8.89M Sell
23,100
-7,000
-23% -$2.58M 0.38% 53
2021
Q2
$7.07M Buy
30,100
+10,100
+51% +$1.8M 0.29% 69
2021
Q1
$2.62M Sell
20,000
-35,900
-64% -$5.2M 0.11% 178
2020
Q4
$5.84M Buy
55,900
+18,400
+49% +$1.86M 0.22% 80
2020
Q3
$2.65M Sell
37,500
-93,700
-71% -$6.53M 0.13% 157
2020
Q2
$8.42M Buy
+131,200
New +$7.19M 0.48% 44

Other funds holding MRNA

CSS LLC's MRNA Position: Q1 2022 in Review

CSS LLC sold out of Moderna (MRNA) in Q1 2022, closing a stake of 3,871 shares — an estimated $652K sold.

CSS LLC first reported a position in MRNA in Q1 2020 and held it in 6 quarters. The position peaked at $3.44M in Q2 2020. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • CSS LLC reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • CSS LLC sold 3,871 Moderna shares in Q1 2022, an estimated $652K.
  • CSS LLC first reported a position in Moderna in Q1 2020 and held it in 6 quarters.
  • CSS LLC's Moderna position peaked at $3.44M in Q2 2020.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on CSS LLC's 13F filing for Q1 2022, filed 16 May 2022.